I focus on producing objective, data-driven research, mostly about small- to mid-cap companies, as these tend to be overlooked by many investors. From time to time, though, I also look at large-cap names, just to give a fuller sense of the broader equity markets.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ...

Have you assessed how the international operations of Haemonetics (HAE) performed in the quarter ended June 2025? For this provider blood management systems for health care providers and blood collectors, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influe ...

Haemonetics Corp HAE reported upbeat earnings for the first quarter on Thursday.The company posted quarterly earnings of $1.10 per share which beat the analyst consensus estimate of $1.02 per share. The company reported quarterly sales of $321.394 million which beat the analyst consensus estimate of $305.115 million.Haemonetics affirmed FY2026 adjusted EPS guidance of $4.70 to $5.00.Haemonetics shares closed at $55.63 on Thursday.These analysts made changes to their price targets on Haemonetics following ea ...

Haemonetics (HAE) reported $321.39 million in revenue for the quarter ended June 2025, representing a year-over-year decline of 4.4%. EPS of $1.10 for the same period compares to $1.02 a year ago.The reported revenue represents a surprise of +5.97% over the Zacks Consensus Estimate of $303.28 million. With the consensus EPS estimate being $1.01, the EPS surprise was +8.91%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine t ...

Haemonetics (HAE) Q1 2026 Earnings Call August 07, 2025 08:00 AM ET Company ParticipantsOlga Guyette - VP - IR & TreasuryChristopher Simon - CEO, President & DirectorJames D’Arecca - EVP & CFORohin Patel - Vice PresidentAnthony Petrone - MD - Equity ResearchAnthony Occhiogrosso - Equity Research Senior AssociateAndrew Cooper - VP - Equity ResearchConference Call ParticipantsDavid Rescott - Senior Research AnalystMike Matson - MD - Senior Equity Research AnalystLarry Solow - Partner & Managing director - Equ ...

Haemonetics (HAE) Q1 2026 Earnings Call August 07, 2025 08:00 AM ET Speaker0Good day and thank you for standing by. Welcome to the Humanetics Corporation First Quarter twenty twenty six Earnings Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone.You will then hear an automated message advising you that your hand is raised. To withdraw y ...

Haemonetics (HAE) came out with quarterly earnings of $1.1 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +8.91%. A quarter ago, it was expected that this provider blood management systems for health care providers and blood collectors would post earnings of $1.22 per share when it actually produced earnings of $1.24, delive ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 28, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☐ 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorporation or organization) ...

Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Communications (781) 356-9763 (781) 356-9776 olga.guyette@haemonetics.com josh.gitelson@haemonetics.com David Trenk, Manager-Investor Relations (203) 733-4987 david.trenk@haemonetics.com | | | 1st Quarter | 2026 | | | --- | --- | --- | --- | --- | | n Revenue, decrease | | $321 million, | (4)% | | | (1) n Organic revenue | increase | 0.5% | | | | (2) n Organic ex-CSL increase | revenue | 12 ...

Group 1 - The article is authored by Terry Chrisomalis, who operates the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace, offering a two-week free trial for new subscribers [1] - Biotech Analysis Central provides a library of over 600 biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, and various analysis and news reports to assist healthcare investors [2] - The subscription for Biotech Analysis Central is priced at $49 per month, with a yearly plan available at a discounted rate of $399, reflecting a 33.50% discount [1][2] Group 2 - The article does not contain any stock, option, or similar derivative positions in the companies mentioned, nor does it plan to initiate any such positions within the next 72 hours [3] - Seeking Alpha clarifies that past performance does not guarantee future results and that no specific investment recommendations are provided [4]